drugset / Trial / NCT00397956

To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)

NCT00397956

Phase 3 Completed 30 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To collect clinical response data with the use of ertapenem in community acquired sepsis.

Timeline

Start
2004-09
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ertapenem Small molecule